{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:43:24Z","timestamp":1776473004650,"version":"3.51.2"},"reference-count":84,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event. Herein, we conducted a quantitative structure\u2013activity relationship analysis using the U.S. Food and Drug Administration Adverse Drug Reaction Database System (FAERS) and machine learning to construct a drug prediction model for MRONJ induction based solely on chemical structure information. Methods: A total of 4815 drugs from FAERS were evaluated, including 70 and 139 MRONJ-positive and MRONJ-negative drugs, respectively, identified based on reporting odds ratios, Fisher\u2019s exact tests, and \u2265100 total adverse event reports. Then, we calculated 326 chemical structure descriptors for each drug and compared three supervised learning algorithms (random forest, gradient boosting, and artificial neural networks). We also compared the number of chemical structure descriptors (5, 6, 7, 8, 9, 10, 20, and 30 descriptors). Results: We indicated that the MRONJ prediction model using an artificial neural network algorithm and eight descriptors achieved the highest validation receiver operating characteristic curve value of 0.778. Notably, the total polar surface area (ASA_P) was among the top-ranking descriptors, and MRONJ-positive drugs such as bisphosphonates and anticancer drugs showed high values. Our final model demonstrated a balanced accuracy of 0.693 and a specificity of 0.852. Conclusions: In this study, our MRONJ-inducing drug prediction model identified drugs with polar surface area properties as potential causes of MRONJ. This study demonstrates a promising approach for predicting MRONJ risk, which could enhance drug safety assessment and streamline drug screening in clinical and preclinical settings.<\/jats:p>","DOI":"10.3390\/ph18030423","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:04:22Z","timestamp":1742209462000},"page":"423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a Medication-Related Osteonecrosis of the Jaw Prediction Model Using the FDA Adverse Event Reporting System Database and Machine Learning"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-0820","authenticated-orcid":false,"given":"Shinya","family":"Toriumi","sequence":"first","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan"},{"name":"Department of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komei","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-991X","authenticated-orcid":false,"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.joms.2021.12.007","article-title":"Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan","volume":"80","author":"Ishimaru","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014A review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Nagata, T., and Urade, M. (2017). Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J. Bone Miner. Metab., 35, 6\u201319.","DOI":"10.1007\/s00774-016-0810-7"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/odi.13160","article-title":"Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges","volume":"25","author":"Schiodt","year":"2019","journal-title":"Oral Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Campisi, G., Mauceri, R., Bertoldo, F., Bettini, G., Biasotto, M., Colella, G., Consolo, U., Di Fede, O., Favia, G., and Fusco, V. (2020). Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17165998"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0140-6736(90)91669-2","article-title":"Quality criteria for early signals of possible adverse drug reactions","volume":"336","author":"Edwards","year":"1990","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kimura, K., Kikegawa, M., Kan, Y., and Uesawa, Y. (2023). Identifying Crude Drugs in Kampo Medicines Associated with Drug-Induced Liver Injury Using the Japanese Adverse Drug Event Report Database: A Comprehensive Survey. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050678"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Toriumi, S., Mimori, R., Sakamoto, H., Sueki, H., Yamamoto, M., and Uesawa, Y. (2023). Examination of Risk Factors and Expression Patterns of Atypical Femoral Fractures Using the Japanese Adverse Drug Event Report Database: A Retrospective Pharmacovigilance Study. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040626"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/clpt.2014.17","article-title":"Exploring the FDA Adverse Event Reporting System to generate hypotheses for monitoring of disease characteristics","volume":"95","author":"Fang","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hosoya, R., Ishii-Nozawa, R., Terajima, T., Kagaya, H., and Uesawa, Y. (2024). The Association between Molecular Initiating Events and Drug-Induced Hiccups. Pharmaceuticals, 17.","DOI":"10.20944\/preprints202402.0808.v1"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ahdi, H.S., Wichelmann, T.A., Pandravada, S., and Ehrenpreis, E.D. (2023). Medication-induced osteonecrosis of the jaw: A review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacol. Toxicol., 24.","DOI":"10.1186\/s40360-023-00657-y"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2146\/ajhp170529","article-title":"Signal detection for bleeding associated with the use of direct oral anticoagulants","volume":"75","author":"Nathan","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CAD.0000000000000862","article-title":"Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System","volume":"2","author":"Sanagawa","year":"2020","journal-title":"Anticancer Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"6","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"7","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Toriumi, S., Kobayashi, A., Sueki, H., Yamamoto, M., and Uesawa, Y. (2021). Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database. Pharmaceuticals, 14.","DOI":"10.3390\/ph14121299"},{"key":"ref_21","unstructured":"(2022, June 05). FDA Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-61779-012-6_2","article-title":"Computer-aided drug discovery and development","volume":"716","author":"Zhang","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.drudis.2022.04.017","article-title":"From traditional to data-driven medicinal chemistry: A case study","volume":"8","author":"Kunimoto","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/194178b0","article-title":"Correlation of Biological Activity of Phenoxyacetic Acids with Hammett Substituent Constants and Partition Coefficients","volume":"194","author":"Hansch","year":"1962","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1021\/ja01062a035","article-title":"p-\u03c3-\u03c0 Analysis. A Method for the Correlation of Biological Activity and Chemical Structure","volume":"86","author":"Hansch","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/ci900161g","article-title":"Benchmark data set for in silico prediction of Ames mutagenicity","volume":"49","author":"Hansen","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.bmcl.2018.08.032","article-title":"Quantitative structure-activity relationship analysis using deep learning based on a novel molecular image input technique","volume":"28","author":"Uesawa","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1021\/acs.jcim.9b00633","article-title":"LightGBM: An Effective and Scalable Algorithm for Prediction of Chemical Toxicity-Application to the Tox21 and Mutagenicity Data Sets","volume":"59","author":"Zhang","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104484","DOI":"10.1016\/j.ijmedinf.2021.104484","article-title":"Comparison of machine learning and logistic regression models in predicting acute kidney injury: A systematic review and meta-analysis","volume":"151","author":"Song","year":"2021","journal-title":"Int. J. Med. Inform."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00586-022-07188-w","article-title":"Machine learning versus logistic regression for prognostic modelling in individuals with non-specific neck pain","volume":"8","author":"Liew","year":"2022","journal-title":"Eur. Spine J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cns.13991","article-title":"Comparison of logistic regression and machine learning methods for predicting postoperative delirium in elderly patients: A retrospective study","volume":"1","author":"Song","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/picr.PICR_87_17","article-title":"Common pitfalls in statistical analysis: Logistic regression","volume":"3","author":"Ranganathan","year":"2017","journal-title":"Perspect. Clin. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/cts.12944","article-title":"In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database","volume":"2","author":"Ambe","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Levy, J.J., and O\u2019Malley, A.J. (2020). Don\u2019t dismiss logistic regression: The case for sensible extraction of interactions in the era of machine learning. BMC Med. Res. Methodol., 20.","DOI":"10.1186\/s12874-020-01046-3"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20200186","DOI":"10.1590\/1677-5449.200186","article-title":"Use of ROC curves in clinical and experimental studies","volume":"19","author":"Polo","year":"2020","journal-title":"J. Vasc. Bras."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Graharm","year":"2011","journal-title":"Bone"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40801-022-00324-4","article-title":"Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Na\u00efve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database","volume":"9","author":"Hasegawa","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pimolbutr, K., Porter, S., and Fedele, S. (2018). Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Na\u00efve Patient: A Comprehensive Review of the Literature. Biomed. Res. Int., 2018.","DOI":"10.1155\/2018\/8071579"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/odi.12490","article-title":"BRONJ in patients with rheumatoid arthritis: A multicenter case series","volume":"22","author":"Bedogni","year":"2016","journal-title":"Oral Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Toriumi, S., Kobayashi, A., and Uesawa, Y. (2020). Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120467"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/ml5004603","article-title":"Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters","volume":"6","author":"Puljula","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20002","DOI":"10.18632\/oncotarget.4755","article-title":"Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: Role in osteoclast-mediated NK cell activation","volume":"24","author":"Tseng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lombard, T., Neirinckx, V., Rogister, B., Gilon, Y., and Wislet, S. (2016). Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem Cells Int., 8768162.","DOI":"10.1155\/2016\/8768162"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","article-title":"Vascular endothelial growth factor receptors in osteoclast differentiation and function","volume":"335","author":"Aldridge","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jnci\/djq516","article-title":"Osteonecrosis of the jaw and the role of macrophages","volume":"103","author":"Pazianas","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107801","DOI":"10.1016\/j.jmgm.2020.107801","article-title":"In silico exploration of binding of selected bisphosphonate derivatives to placental alkaline phosphatase via docking and molecular dynamics","volume":"103","author":"Madaj","year":"2021","journal-title":"J. Mol. Graph. Model."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhuravleva, I.Y., Dokuchaeva, A.A., Karpova, E.V., Timchenko, T.P., Titov, A.T., Shatskaya, S.S., and Polienko, Y.F. (2021). Immobilized Bisphosphonates as Potential Inhibitors of Bioprosthetic Calcification: Effects on Various Xenogeneic Cardiovascular Tissues. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010065"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2011.89","article-title":"The FDA drug safety surveillance program: Adverse event reporting trends","volume":"171","author":"Deshpande","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: Signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_60","first-page":"1","article-title":"Data Quality Considerations for Big Data and Machine Learning: Going Beyond Data Cleaning and Transformations","volume":"10","author":"Gudivada","year":"2017","journal-title":"Int. J. Adv. Softw."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csda.2017.01.005","article-title":"RHSBoost: Improving classification performance in imbalance data","volume":"111","author":"Joonho","year":"2017","journal-title":"Comput. Stat. Data Anal."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ezzat, A., Wu, M., Li, X.L., and Kwoh, C.K. (2016). Drug-target interaction prediction via class imbalance-aware ensemble learning. BMC Bioinform., 17.","DOI":"10.1186\/s12859-016-1377-y"},{"key":"ref_63","unstructured":"(2022, July 03). ATC\/DDD Index. Available online: https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"ref_64","first-page":"4007","article-title":"Convolutional Neural Networks for ATC Classification","volume":"34","author":"Lumini","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_65","unstructured":"(2022, July 01). ICH Harmonisation for Berrer Health. Available online: https:\/\/www.ich.org\/."},{"key":"ref_66","unstructured":"(2022, July 03). MedDRA; Medical Dictionary for Regulatory Activities. Available online: https:\/\/www.meddra.org\/how-to-use\/support-documentation\/japanese\/welcome."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kan, Y., Nagai, J., and Uesawa, Y. (2021). Evaluation of antibiotic-induced taste and smell disorders using the FDA Adverse Event Reporting System database. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-88958-2"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Okunaka, M., Kano, D., and Uesawa, Y. (2022). Nuclear receptor and stress response pathways associated with antineoplastic agent-induced diarrhea. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012407"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/bmt.2017.158","article-title":"Association between GvHD and nivolumab in the FDA Adverse Event Reporting System","volume":"52","author":"Oshima","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_72","unstructured":"European Medicines Agency (2022, July 05). \u201cGuideline on the Use of Statistical Signal Detection Methods in the Eudravigilance Data Analysis System\u201d. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kurosaki, K., and Uesawa, Y. (2021). Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. Biomolecules, 11.","DOI":"10.3390\/biom11070944"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.tpj.6500412","article-title":"Selection of differentially expressed genes in microarray data analysis","volume":"7","author":"Chen","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cui, X., and Churchill, G.A. (2003). Statistical tests for differential expression in cDNA microarray experiments. Genome Biol., 4.","DOI":"10.1186\/gb-2003-4-4-210"},{"key":"ref_76","unstructured":"(2022, July 01). PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"ref_77","unstructured":"(2022, July 18). MOE. Available online: https:\/\/www.chemcomp.com\/Products.htm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1214\/aos\/1013203451","article-title":"Greedy function approximation: A gradient boosting machine","volume":"29","author":"Friedman","year":"2001","journal-title":"Ann. Statist."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0893-6080(89)90020-8","article-title":"Multilayer feedforward networks are universal approximators","volume":"2","author":"Hornik","year":"1989","journal-title":"Neural Netw."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","article-title":"Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans","volume":"3","author":"Mamada","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s11030-021-10348-7","article-title":"Construction of a prediction model for drug removal rate in hemodialysis based on chemical structures","volume":"5","author":"Nishikiori","year":"2022","journal-title":"Mol. Divers."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.3390\/molecules17054791","article-title":"Comparison of different approaches to define the applicability domain of QSAR models","volume":"17","author":"Sahigara","year":"2012","journal-title":"Molecules"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","article-title":"Understanding diagnostic tests 3: Receiver operating characteristic curves","volume":"96","author":"Akobeng","year":"2007","journal-title":"Acta Paediatr."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:06Z","timestamp":1760028906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030423"],"URL":"https:\/\/doi.org\/10.3390\/ph18030423","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}